Tabalumab, fully anti-BAFF humanized monoclonal antibodies, has been tested in patients with relapsing-remitting multiple sclerosis in a phase II randomized, double-blind, placebo-controlled study (ClinicalTrials.gov study identifier: NCT00882999). The gene discussed is TNFSF13B; the disease is relapsing-remitting multiple sclerosis.